Controversial US-backed hepatitis B vaccine trial to move forward in Guinea-Bissau

A US-backed hepatitis B vaccine trial has been approved to continue in Guinea-Bissau, despite concerns about its ethics. This decision has sparked debate about the trial's impact on the local population and the potential risks associated with the vaccine. The trial's approval could have implications for global health policies and the way pharmaceutical companies conduct clinical trials in developing countries, particularly in Africa. The outcome of this trial may influence future decisions regarding vaccine development and distribution.

Why it matters

The US-backed hepatitis B vaccine trial in Guinea-Bissau has raised ethical concerns. The trial's approval despite these concerns could lead to a loss of public trust in medical research and the government's handling of healthcare issues.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to Africanews. For information only — not financial advice.